Scott Spector

Mr. Spector is an accomplished clinical development executive with 20 years of experience in pharmaceutical product development. He was previously the European President of Siro Clinpharm, an emerging market CRO with a strong focus on the CEE and India. His career in clinical development began at Quintiles Transnational, where he played a key role in expanding the company’s European operations. Scott served as the President of Quintiles France and Spain and led the global operations for the CNS and Anti-Infectives business units. After a decade at Quintiles, he became President of CAC Oncology, a pioneering firm in oncology contract research services and drug development consulting. Following the sale of CAC Oncology to AAIPharma, he became President of a new entity called AAI Oncology. He holds a BS/BA in Finance from Boston University and a Professional Certificate in Genetics and Genomics from Stanford University.